

FIG. 1


























FIG. 2



163

























Fig. 5






$$\text{CH}_3(\text{CH}_2)_{13}\text{NHCH}_2\text{CH}_2\text{CH}_2\text{SO}_3\text{H}$$


$$\text{CH}_3(\text{CH}_2)_{15}\text{NHCH}_2\text{CH}_2\text{CH}_2\text{SO}_3\text{H}$$

$$\text{CH}_3(\text{CH}_2)_{17}\text{NHCH}_2\text{CH}_2\text{CH}_2\text{SO}_3\text{H}$$


FIG. 8



I




III




IV


II




V




VI




VII




VIII




IX




X




XI




XII




XIII




XIV




XV




XVI




XVII



XVIII













XIX



XX

FIG. 9



L










FIG. II




LV




LVI




LVII




LVIII




LIX



LX



LXI




LXII




LXIII

FIG. 12


四庫全書




LXIV




LXV




LXVI




LXVII




LXVIII




LXIX




LXX




LXXI



LXXII




LXXIII




LXXIV


FIG. 13



LXXV



LXXVI



LXXVII

FIG. 14




FIGURE 15

RANTES (80ng/ml) binding inhibition with heparin in Elisa




FIGURE 16

ELISA

RANTES (80ng/ml) binding
inhibition




FIGURE 17

RANTES (80ng/ml) binding
inhibition

ELISA




FIGURE 18




FIGURE 19

ELISA

IL-8 (80ng/ml) binding
inhibition





FIGURE 20

ELISA RANTES (80ng/ml) binding inhibition
with compound



■ 4
Heparin coated wells
(40 ng/well)

FIGURE 21

ELISA

IL-8 (80ng/ml) binding inhibition
with compound




FIGURE 22

ELISA

Binding inhibition





FIGURE 23

ELISA

EOTAXIN (80ng/ml) binding
inhibition



4
Heparin coated wells
(40ng/well)

FIGURE 24

ELISA

EOTAXIN (80ng/ml) binding inhibition




FIGURE 25

ELISA

EOTAXIN (80ng/ml) binding
inhibition




FIGURE 26

ELISA RANTES (80ng/ml) binding inhibition
with compounds




FIGURE 27

F02007-84T027560




FIGURE 28